EDEducation Center

Tysabri Home Infusion & TOUCH Program Guide

Tysabri Home Infusion: Navigating the TOUCH Program and What It Means for Patients

Tysabri (natalizumab) is one of the most effective treatments for relapsing multiple sclerosis, but receiving it at home is more complicated than with most other biologics. The mandatory TOUCH Prescribing Program adds layers of registration, monitoring, and pharmacy certification that patients must understand before pursuing home infusion. Here is what that process actually involves — and where the real obstacles lie.

[Image: Close-up of TOUCH program enrollment documentation alongside Tysabri infusion supplies]

What the TOUCH Program Requires

The TOUCH (Tysabri Outreach: Unified Commitment to Health) Prescribing Program is an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS). It exists because Tysabri carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the JC virus. Every patient, prescriber, infusion center, and pharmacy involved in Tysabri treatment must be enrolled in TOUCH.

For home infusion specifically, the TOUCH requirements include:

  • Patient enrollment: Patients must complete and sign a TOUCH enrollment form acknowledging the risks of PML, and must re-authorize every 6 months.
  • Prescriber certification: The neurologist must be registered with the TOUCH program and must complete prescribing authorization before each infusion cycle.
  • Pharmacy and infusion site certification: The home infusion pharmacy dispensing and the nurse administering Tysabri must both be TOUCH-certified. Not all home infusion pharmacies carry this certification.
  • Pre-infusion questionnaire: Before every infusion, patients must answer screening questions about new neurological symptoms that could indicate PML.
Critical Point: The TOUCH program is not optional or negotiable. If any link in the chain — patient, prescriber, pharmacy, or nurse — is not properly enrolled and up to date, the infusion cannot proceed. Patients have reported infusions being delayed or cancelled due to administrative lapses, such as an expired re-authorization form. Staying proactive about renewal deadlines is essential.

Finding a Certified Home Infusion Pharmacy

This is where many patients hit an unexpected wall. Unlike Remicade or Entyvio, which can be dispensed by virtually any licensed home infusion pharmacy, Tysabri requires the pharmacy to hold specific TOUCH certification. The pool of eligible pharmacies is smaller, and in some geographic areas, options may be limited.

When evaluating a home infusion pharmacy for Tysabri, patients should confirm:

  • The pharmacy is TOUCH-certified and currently active in the program
  • The nurses the pharmacy dispatches are individually TOUCH-certified
  • The pharmacy is in the patient’s insurance network
  • The pharmacy has experience specifically with Tysabri home infusion (not just general biologics)

A common frustration: a patient’s preferred home infusion pharmacy may handle dozens of other biologics but lack TOUCH certification. Switching pharmacies solely for Tysabri can create administrative complications with insurance and care coordination.

Key Takeaway: Before committing to home Tysabri infusion, verify pharmacy TOUCH certification first. This single factor determines whether home infusion is even possible in a given area. The prescriber’s office can often help identify certified pharmacies, or patients can contact Biogen’s TOUCH support line directly.

JC Virus Monitoring at Home

JC virus antibody testing is a cornerstone of Tysabri safety monitoring. Patients receive blood tests — typically every 6 months — to check for JC virus antibody status. A positive result does not necessarily mean Tysabri must be stopped, but it changes the risk calculus significantly, particularly for patients who have been on Tysabri for more than 2 years.

[Image: Diagram showing the JC virus antibody index levels and their relationship to PML risk over time on Tysabri]

For patients receiving Tysabri at home, the JC virus monitoring adds a logistical layer. The blood draw for antibody testing needs to happen at regular intervals, and this requires coordination between the neurologist, the lab, and the home infusion team. Some approaches include:

  • The home infusion nurse draws labs during an infusion visit, which is efficient but requires standing lab orders
  • The patient visits a local lab separately for blood draws
  • Mobile phlebotomy services are arranged through the home infusion pharmacy

According to the National MS Society, patients who are JC virus antibody positive — especially those with an antibody index above 1.5 who have been on Tysabri for over 2 years or have prior immunosuppressant use — face the highest PML risk. These patients require the most vigilant monitoring regardless of infusion setting.

A subtlety that clinic patients may take for granted: in a medical office, MRI scheduling reminders and lab result follow-ups are often built into the workflow. At home, patients may need to be more proactive in ensuring these monitoring steps happen on schedule. Keeping a personal calendar of due dates for JC virus testing and brain MRIs is a practical safeguard.

What Infusion Day Looks Like

The Tysabri infusion itself is relatively straightforward compared to its regulatory overhead. Here is the typical protocol:

  1. Pre-infusion screening: The nurse completes the required TOUCH questionnaire with the patient, verifying no new or worsening neurological symptoms
  2. Vitals check: Blood pressure, temperature, and pulse are recorded
  3. Infusion: Tysabri is infused intravenously over approximately 1 hour
  4. Post-infusion observation: The patient must be observed for 1 hour after the infusion ends — this is a TOUCH program requirement, not optional

Total appointment time runs approximately 2.5 to 3 hours including setup and documentation. Premedication is not routinely required for Tysabri, though individual prescribers may order it for patients who have experienced mild reactions.

The 1-Hour Observation Is Mandatory: Unlike some other biologics where post-infusion observation periods can be adjusted based on patient history, the 1-hour post-infusion monitoring for Tysabri is a fixed TOUCH requirement. The nurse must remain with the patient for the full hour, even if the patient has tolerated dozens of previous infusions without incident.

Weighing the Decision

Tysabri home infusion is achievable but demands more advance planning than home infusion of most other biologics. Patients should weigh several factors:

Consideration Home Infusion Clinic/Center
TOUCH compliance Patient must track re-enrollments Clinic staff often manage paperwork
Pharmacy availability Limited to TOUCH-certified pharmacies Most infusion centers are certified
Lab coordination Requires separate arrangement Often integrated with visit
Convenience No travel; home comfort Requires travel; structured setting
Total time commitment ~3 hours at home ~3 hours plus travel time

For patients with mobility challenges from MS, or those who live far from a certified infusion center, the convenience gains of home infusion can be substantial despite the added administrative complexity. Patients exploring MS home infusion options more broadly may want to compare how different MS treatments align with their priorities. The broader comparison of home infusion versus infusion centers also provides useful context for this decision.

Key Takeaway: Tysabri home infusion is possible but requires navigating the TOUCH program’s unique requirements. The biggest practical barriers are pharmacy certification and lab coordination — not the infusion itself. Patients who plan ahead and stay organized around TOUCH deadlines generally find the transition manageable.

Sources

  1. FDA. Tysabri (natalizumab) REMS — TOUCH Prescribing Program. fda.gov
  2. National MS Society. Tysabri treatment overview and PML risk. nationalmssociety.org
  3. National Institutes of Health. Progressive multifocal leukoencephalopathy and natalizumab. ncbi.nlm.nih.gov
  4. NINDS. Progressive multifocal leukoencephalopathy information page. ninds.nih.gov
  5. Mayo Clinic. Natalizumab — uses, risks, and monitoring. mayoclinic.org
  6. Cleveland Clinic. MS treatment: disease-modifying therapies. clevelandclinic.org
  7. American Academy of Neurology. MS disease-modifying therapy guidelines. aan.com
  8. MedlinePlus. Natalizumab injection. medlineplus.gov
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The TOUCH program requirements described here are subject to change — always verify current requirements with the prescribing neurologist and Biogen directly. Infusionary is an independent patient education platform and does not provide medical care.

Ready to take the next step?

Find a specialist who starts and manages this therapy, or an infusion center near you — every listing verified.